Loading
A stain on the tumour biopsy that measures how much of the PD-L1 'don't attack me' protein is present, scored as a tumour proportion or combined positive score. Higher levels usually mean checkpoint inhibitors work better, and approvals in lung, triple-negative breast, gastric and head and neck cancer set minimum scores; yet PD-L1-negative tumours sometimes respond.
Several antibody clones (22C3 for pembrolizumab, SP142 for atezolizumab, SP263 for durvalumab, 28-8 for nivolumab) and scoring systems (tumour proportion score, combined positive score, immune cell score) are in use and are only partly interchangeable (Blueprint project), which complicates practice. PD-L1 ≥50% TPS in lung cancer permits pembrolizumab alone; CPS ≥10 gates pembrolizumab in triple-negative breast and CPS ≥1 or ≥5 in gastric and head and neck cancer. It is an imperfect biomarker: PD-L1-negative tumours sometimes respond and expression is heterogeneous and changes with treatment.
In plain words · PD-L1 is the tumour's side of the PD-1 brake, and also the biomarker that decides who gets immunotherapy.
Showing the target this term concerns: PD-L1.
The glossary entry explains the word; the readout page carries the scoring rule, the thresholds approvals use, the companion diagnostics and the tests.
Shares KEYNOTE-001 (Garon 2015): pembrolizumab in non-small-cell lung cancer and the 50% PD-L1 cut-off, CheckMate 057, CheckMate 017, IMpower110.
Shares KEYNOTE-001 (Garon 2015): pembrolizumab in non-small-cell lung cancer and the 50% PD-L1 cut-off, PD-L1 TC score (tumour-cell score, SP263 and 28-8), PD-L1 IC score (immune-cell score, SP142), VENTANA PD-L1 (SP142) Assay.
Shares VENTANA PD-L1 (SP263) Assay, PD-L1 IC score (immune-cell score, SP142), PD-L1 IHC 22C3 pharmDx, VENTANA PD-L1 (SP142) Assay.
Shares PD-L1 IC score (immune-cell score, SP142), PD-L1 IHC 22C3 pharmDx, VENTANA PD-L1 (SP142) Assay, PD-L1 CPS (combined positive score).
Shares PD-L1 TC score (tumour-cell score, SP263 and 28-8), PD-L1 IC score (immune-cell score, SP142), PD-L1 TPS (tumour proportion score), Histopathology & immunohistochemistry.
Shares PD-L1 TC score (tumour-cell score, SP263 and 28-8), PD-L1 IC score (immune-cell score, SP142), PD-L1 TPS (tumour proportion score), Histopathology & immunohistochemistry.
Shares PD-L1 TC score (tumour-cell score, SP263 and 28-8), PD-L1 IC score (immune-cell score, SP142), PD-L1 TPS (tumour proportion score), Histopathology & immunohistochemistry.
Shares IMpower110, KEYNOTE-010, CheckMate 026, PD-L1-high non-small-cell lung cancer without a driver mutation.